Clearmind Medicine Announces Publication Of Six Patents By IP Department In Hong Kong Covering Proprietary Combination Therapies Integrating Palmitoylethanolamide

Clearmind Medicine Inc. (NASDAQ: CMND) has announced the publication of six patents by the Intellectual Property Department in Hong Kong, which cover proprietary combination therapies that integrate Palmitoylethanolamide (PEA) with various psychedelic compounds, including MDMA, LSD, and Ketamine. These patents protect innovative formulations aimed at enhancing therapeutic potential and improving safety and tolerability for mental health and neurological conditions. The developments are part of Clearmind's focus on creating non-hallucinogenic therapeutics through its partnership with NeuroThera Labs Inc.